US · EMBC
Embecta Corp.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Parsippany, NJ 07054
- Website
- embecta.com
Price · as of 2025-09-30
$9.23
Market cap 607.6M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $37.30 | +304.12% |
| Intrinsic Value(DCF) | $5.69 | -38.35% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $7.36 | -20.31% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $47.26 | $45.21 | |||
| 2021 | $46.69 | $111.06 | |||
| 2022 | $27.89 | $91.52 | $2.87 | $1.44 | $20.62 |
| 2023 | $16.15 | $62.00 | $0.40 | $0.00 | $9.06 |
| 2024 | $17.94 | $49.11 | $0.00 | $0.00 | $11.15 |
| 2025 | $11.37 | $37.30 | $1.59 | $0.00 | $7.36 |
AI valuation
Our deep-learning model estimates Embecta Corp.'s (EMBC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $37.30
- Current price
- $9.23
- AI upside
- +304.12%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.69
-38.35% upside
Graham-Dodd
—
— upside
Graham Formula
$7.36
-20.31% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EMBC | Embecta Corp. | $9.23 | 607.6M | +304% | -38% | — | -20% | 6.95 | -1.02 | 0.61 | 6.34 | 33.27 | -0.99 | 62.89% | 30.48% | 8.83% | -13.74% | 39.85% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 2090.00% | -380.00% | 81658.00% | 27.50% | 0.73 | 31.54% | 5.28% | 36.70% | 26.66% | 5.67 | 10.24 | 1.73 | 2.05 |
| AQST | Aquestive Therapeutics, I… | $4.00 | 397.23M | +466% | -73% | — | — | -5.21 | -3.82 | 3.99 | -7.37 | -1.78 | -3.82 | 68.95% | -53.46% | -76.68% | 52.97% | 32.25% | -55.57% | -0.63 | -1.83 | 4.68 | 4.18 | 1.26 | 29231.00% | 1380.00% | 38702.00% | -15.63% | -1.90 | 37.66% | 0.00% | 0.00% | 18.71% | -6.38 | -5.46 | 3.41 | -3.77 |
| CDNA | CareDx, Inc | $18.76 | 964.88M | +90% | -24% | -84% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| EBS | Emergent BioSolutions Inc… | $8.15 | 434.81M | +481% | -56% | +80% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| EVH | Evolent Health, Inc. | $3.25 | 376.91M | +378% | -56% | — | +2,393% | -0.71 | 0.98 | 0.22 | -0.76 | -0.13 | -0.47 | 15.09% | -0.24% | -28.49% | -81.81% | -0.48% | -26.08% | 0.05 | -0.08 | 1.31 | 1.23 | 0.37 | 52593.00% | -2656.00% | -17759.00% | 1.16% | 0.10 | 0.52% | 2.72% | -1.90% | 194.02% | -62.28 | 58.08 | 0.15 | 0.25 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| MYGN | Myriad Genetics, Inc. | $4.61 | 429.72M | +702% | -57% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| SIGA | SIGA Technologies, Inc. | $6.47 | 463.33M | +352% | -48% | — | -5% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
- CEO
- Devdatt Kurdikar
- Employees
- 2K
- Beta
- 1.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.69 ÷ $9.23) − 1 = -38.35% (DCF, example).